Brief: Moleculin Accelerates Planned Unblinded Data Readout For Miracle Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial To H2 2025
14/11/2024 13:22
Nov 14 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN ACCELERATES PLANNED UNBLINDED DATA READOUT FOR
MIRACLE
PHASE 3 R/R ACUTE MYELOID LEUKEMIA (AML) PIVOTAL TRIAL TO H2
2025
* MOLECULIN ACCELERATES PLANNED UNBLINDED DATA READOUT FOR
MIRACLE
PHASE 3 R/R ACUTE MYELOID LEUKEMIA (AML) PIVOTAL TRIAL TO H2
2025
* MOLECULIN BIOTECH INC - FIRST SUBJECT TREATMENT IN MIRACLE
TRIAL
EXPECTED Q1 2025
Source text: ID:nPn3cx5RBa
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM